My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Novo Nordisk A/S Common Stock (NY:NVO)

39.51 -7.91 (-16.69%)

Streaming Delayed Price Updated: 3:17 PM EST, Feb 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

99 100 Next >

Hims & Hers Faces FDA Heat As Commissioner Martin Makary Calls Out Super Bowl Ad For Hiding Drug Risks ↗

September 13, 2025

FDA Commissioner Martin Makary said Hims & Hers broke federal law with its Super Bowl ad promoting weight-loss drugs without disclosing side effects, and called it "the most overt breach" of FDA...

Via Benzinga

The Dawn of a New Era: How GLP-1s, AI, and Robotic Surgery Are Reshaping Healthcare and Investment

September 12, 2025

The healthcare industry is currently experiencing a transformative "golden age," a period marked by an unprecedented surge in scientific breakthroughs and technological advancements. This era is...

Via MarketMinute

Eli Lilly, Novo Nordisk Preparing To Introduce Obesity Pills Next Year In The US: Report ↗

September 12, 2025

Via Stocktwits

Why Is Novo Nordisk’s Stock Rising Premarket Today? ↗

September 10, 2025

Via Stocktwits

Eli Lilly, Novo Nordisk’s Weight-Loss Drugs Deemed Cost-Effective By Pricing Watchdog: BofA Deems Decision A ‘Win’ ↗

September 09, 2025

Via Stocktwits

Chinese Drugmakers Flooded US With Wegovy Copy Ingredients — Now They Are Pivoting To Generics: Report ↗

September 03, 2025

Via Stocktwits

How Do Investors Really Feel About Novo Nordisk? ↗

September 12, 2025

Via Benzinga

Prediction: After a Tough Summer for Healthcare Stocks, These 2 Companies Can Make a Comeback ↗

September 11, 2025

One of them is already a leader in the market for weight management drugs, and the other could join this field.

Via The Motley Fool

Topics ETFs

2 Undervalued Healthcare Stocks to Buy in 2025 and Hold for Decades ↗

September 11, 2025

A decade from now, you could regret ignoring these no-brainer stock picks.

Via The Motley Fool

Topics Intellectual Property

China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order ↗

September 10, 2025

Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs.

Via Investor's Business Daily

Topics Government

Novo Nordisk Tightens Its Belt, Cutting 9,000 Jobs And Its Profit Outlook ↗

September 10, 2025

Novo Nordisk announced a "sweeping transformation" Wednesday as the drugmaker contends with challenges in obesity.

Via Investor's Business Daily

Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets ↗

September 10, 2025

ICER finds semaglutide and tirzepatide cost-effective for obesity but flags major affordability concerns and limited patient access at current prices.

Via Benzinga

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): A Prime Value Candidate with Strong Fundamentals ↗

September 10, 2025

Discover Novo Nordisk (NVO), a strong value investing candidate. It offers solid valuation, top-tier profitability, and robust growth in the pharmaceutical sector.

Via Chartmill

Novo Nordisk To Cut 9,000 Jobs As Competition From Eli Lilly Heats Up: Analyst Calls Move 'Tough, Natural...Very Necessary' ↗

September 10, 2025

Novo Nordisk (NYSE: NVO) has announced a significant restructuring plan that will see the company cut 9,000 jobs, representing 11.5% of its workforce. The decision comes as the pharmaceutical giant...

Via Benzinga

Why Novartis' $1.4 Billion Takeover Of Tourmaline Bio Just 'Makes Sense' ↗

September 09, 2025

Novartis agreed to buy a cardiovascular-focused biotech company

Via Investor's Business Daily

Novartis Snaps Up Cardio-Focused Tourmaline Bio For $1.4 Billion ↗

September 09, 2025

Tourmaline Bio shares skyrocketed Tuesday after Novartis agreed to buy the cardiovascular-focused biotech company.

Via Investor's Business Daily

1 Reason Every Investor Should Know About Novo Nordisk (NVO) ↗

September 08, 2025

The company could be on the verge of turning the tide in the battle over weight loss drugs.

Via The Motley Fool

Ozempic Is The New Botox And Big Pharma Is Printing Billions ↗

September 08, 2025

Ozempic and Zepbound have helped Novo Nordisk and Eli Lilly achieve a combined market cap topping $900 billion.

Via Benzinga

FDA Tightens Grip On Safe Weight Loss Drugs, WHO Adds Them To Essential Medicines List ↗

September 07, 2025

FDA introduces a green list to block unsafe GLP-1 drug imports, while WHO updates its essential medicines list to include diabetes and cancer treatments.

Via Benzinga

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data ↗

September 05, 2025

Skye Bioscience's latest data show nimacimab boosted tirzepatide's weight loss effects and reduced obesity treatment rebound risk.

Via Benzinga

Down 34%, Should You Buy the Dip on Viking Therapeutics? ↗

September 05, 2025

Viking aims to enter the billion-dollar weight loss drug market.

Via The Motley Fool

Where Will Eli Lilly Be in 3 Years? ↗

September 04, 2025

The weight-loss drug opportunity could approach $100 billion by the end of the decade.

Via The Motley Fool

Topics Intellectual Property

The Problem With Weight Loss Stocks ↗

September 03, 2025

There are new ways to tackle weight loss, but the stocks leading the way are lagging.

Via The Motley Fool

Topics Economy

After Copycat Boom, China's Drugmakers Target Global Generics ↗

September 03, 2025

Chinese suppliers of semaglutide and tirzepatide that fueled a U.S. weight-loss drug boom are pivoting to generics as FDA crackdowns.

Via Benzinga

Topics Supply Chain

Should You Buy Novo Nordisk Stock Now or Wait? ↗

September 03, 2025

NVO stock is down 60% over the past 12 months.

Via The Motley Fool

Is Novo Nordisk Stock a Buy Now? ↗

September 03, 2025

A 57% risk reduction for heart attacks and strokes sounds like an amazing result.

Via The Motley Fool

Marjorie Taylor Greene Hits Homerun Again, Buys Alphabet Stock 5 Days Before Favorable Antitrust Ruling: Here Are Some Other New Trades ↗

September 03, 2025

Rep. Marjorie Taylor Greene buys Google stock just days before a key antitrust ruling. See her latest trades and portfolio performance.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

September 02, 2025

Via Benzinga

Novo Nordisk's Wegovy Outshines Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke And Death ↗

September 02, 2025

Novo Nordisk's Wegovy cut cardiovascular risks significantly versus tirzepatide in a real-world study, showing fewer heart attacks, strokes, and deaths.

Via Benzinga

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) Emerges as a Top Affordable Growth Stock ↗

August 30, 2025

NOVO-NORDISK (NVO) is a top GARP stock with strong growth, high profitability, and a reasonable valuation, making it a compelling investment opportunity.

Via Chartmill

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.